OncLiveTargeting CD19 May Yield Paradigm-Altering TechnologyOncLiveFor the past two decades, researchers have been exploring B-cell specific antigens in hopes of developing a new anticancer target that would mirror the success of the CD20-targeting rit…
|
Research and Markets: Analytical Tool – The Commercial Success of Cancer …
Business Wire (press release) “Analytical Tool – Cancer Therapeutic Antibodies” offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody drug development for the treatment of cancer. It is at the same time a map of the research and … |
|
Alzheimer’s Antibodies: Can the Current Ones Even Work?
Corante As everyone in the field knows, there’s a lot of work that has been poured into anti-beta-amyloid antibodies as a potential therapy for Alzheimer’s. There are plenty of questions, starting with the amyloid hypothesis itself, but even if you stipulate … |
|
Oxford BioTherapeutics Wins Rights to Amgen Antibodies, ImmunoGen ADC …
Genetic Engineering News Oxford BioTherapeutics said today it obtained exclusive global rights to some of Amgen’s Xenomouse® antibodies and ImmunoGen’s maytansinoid antibody-drug conjugate (ADC) technology, with plans to develop a new ADC targeting an undisclosed … Oxford BioTherapeutics Takes Exclusive Rights to Use Amgen Xenomouse …MarketWatch |
|
Dako launches new cancer diagnostic antibodies
Zenopa Both antibodies provide optimal staining results enabled by Dako’s FLEX Ready-to-Use (RTU) solutions, a plug-and-play solution consisting of pre-diluted antibodies, a visualisation system and optimised validated protocols. Hans Christian Pedersen … |
Dr Valentin Goede: New anti CD-20 agent for the treatment of CLLMD-FM The first medical webradioCurrently, the anti-CD-20 monoclonal antibody rituximab is a standard of care for these patients. A second anti-CD-20 antibody, ofatumumab came out in 2012,…
Antibodies Block Migraine in Early TrialsMedPage TodayBoth men were reporting on trials of different antibodies to a substance thought to play a central role in migraine — calcitonin gene-related peptide, or CGRP. And results of the trials — both sma…
Biologic agents do not up recurrent cancer risk in RAThe Oncology ReportThe hazard ratios, adjusted for age and sex, for recurrent cancer were 0.55 for patients treated with drugs directed at tumor necrosis factor (TNF)-alpha and 0.47 for patients trea…
Dako, an Agilent Technologies Company, Launches Two Ready-to-Use …SelectScience.net (press release)Dako, an Agilent Technologies company and worldwide provider of cancer diagnostic solutions, today announced the addition of two new antibodies, Anti-C…
Dako, an Agilent Technologies Company, Launches Two Ready-to-Use …Virtual-Strategy Magazine (press release)GLOSTRUP, Denmark, May 2, 2014 (GLOBE NEWSWIRE) — Dako, an Agilent Technologies company and worldwide provider of cancer diagnostic solutions …